Furthermore, promoting the expression of FOXD3 is beneficial for the prognosis of patients with neuroblastoma (Li et al., 2013), whereas inhibiting FOXD3 expression is detrimental to the prognosis of breast cancer patients (Chu et al., 2014). Here, FOXD3 is linked to breast cancer.